Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $199.5333.

PVLA has been the subject of a number of recent research reports. BTIG Research increased their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Chardan Capital restated a “buy” rating and set a $240.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Stephens restated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st.

Insiders Place Their Bets

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. bought a new position in Palvella Therapeutics during the 3rd quarter worth approximately $21,255,000. Aberdeen Group plc bought a new position in Palvella Therapeutics during the 3rd quarter worth approximately $3,212,000. First Light Asset Management LLC bought a new position in Palvella Therapeutics during the 3rd quarter worth approximately $33,949,000. Suvretta Capital Management LLC lifted its holdings in Palvella Therapeutics by 15.1% during the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after buying an additional 107,937 shares during the last quarter. Finally, Apis Capital Advisors LLC bought a new position in Palvella Therapeutics during the 3rd quarter worth approximately $627,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

PVLA stock opened at $115.86 on Friday. Palvella Therapeutics has a 1 year low of $20.20 and a 1 year high of $151.18. The firm has a market cap of $1.66 billion, a P/E ratio of -27.78 and a beta of -0.13. The stock has a 50-day simple moving average of $121.09 and a 200-day simple moving average of $106.76.

Palvella Therapeutics (NASDAQ:PVLA) last posted its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities research analysts predict that Palvella Therapeutics will post -5.26 EPS for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.